Cargando…

Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy

The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Kumanan, Graham, Ian, Ricketts, Maura, Dornan, Christopher, Laupacis, Andreas, Hebert, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126723/
https://www.ncbi.nlm.nih.gov/pubmed/17014945
http://dx.doi.org/10.1016/j.socscimed.2006.08.023
_version_ 1783516208179445760
author Wilson, Kumanan
Graham, Ian
Ricketts, Maura
Dornan, Christopher
Laupacis, Andreas
Hebert, Paul
author_facet Wilson, Kumanan
Graham, Ian
Ricketts, Maura
Dornan, Christopher
Laupacis, Andreas
Hebert, Paul
author_sort Wilson, Kumanan
collection PubMed
description The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substantial reform. Variant Creutzfeldt–Jakob (vCJD) disease was the first infectious threat faced by the blood system since undergoing reform. The response at the time to this risk provides insights into the Canadian blood system's new approach to infectious threats. Our analysis of the decision-making concerning vCJD identifies two dominant themes characterizing the new blood system's approach to safety: (1).. the adoption of a precautionary approach to new risks which involves taking action in advance of definitive evidence, and (2).. risk aversion amongst policy makers, which has contributed to the adoption of safety measures with comparatively high cost-effectiveness ratios. Overall the principles governing the new blood system have contributed to the system both providing protection against emerging infectious risks and regaining the confidence of the public and recipients. However, the current set of policy factors will likely contribute to increasingly risk-averse policy making that will contribute to continued increases in the cost of the blood system. The challenge the blood system now faces is to find the appropriate balance between maximizing safety and ensuring the system remains affordable.
format Online
Article
Text
id pubmed-7126723
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71267232020-04-08 Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy Wilson, Kumanan Graham, Ian Ricketts, Maura Dornan, Christopher Laupacis, Andreas Hebert, Paul Soc Sci Med Article The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substantial reform. Variant Creutzfeldt–Jakob (vCJD) disease was the first infectious threat faced by the blood system since undergoing reform. The response at the time to this risk provides insights into the Canadian blood system's new approach to infectious threats. Our analysis of the decision-making concerning vCJD identifies two dominant themes characterizing the new blood system's approach to safety: (1).. the adoption of a precautionary approach to new risks which involves taking action in advance of definitive evidence, and (2).. risk aversion amongst policy makers, which has contributed to the adoption of safety measures with comparatively high cost-effectiveness ratios. Overall the principles governing the new blood system have contributed to the system both providing protection against emerging infectious risks and regaining the confidence of the public and recipients. However, the current set of policy factors will likely contribute to increasingly risk-averse policy making that will contribute to continued increases in the cost of the blood system. The challenge the blood system now faces is to find the appropriate balance between maximizing safety and ensuring the system remains affordable. Elsevier Ltd. 2007-01 2006-10-02 /pmc/articles/PMC7126723/ /pubmed/17014945 http://dx.doi.org/10.1016/j.socscimed.2006.08.023 Text en Copyright © 2006 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Wilson, Kumanan
Graham, Ian
Ricketts, Maura
Dornan, Christopher
Laupacis, Andreas
Hebert, Paul
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title_full Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title_fullStr Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title_full_unstemmed Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title_short Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
title_sort variant creutzfeldt–jakob disease and the canadian blood system after the tainted blood tragedy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126723/
https://www.ncbi.nlm.nih.gov/pubmed/17014945
http://dx.doi.org/10.1016/j.socscimed.2006.08.023
work_keys_str_mv AT wilsonkumanan variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy
AT grahamian variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy
AT rickettsmaura variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy
AT dornanchristopher variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy
AT laupacisandreas variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy
AT hebertpaul variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy